Stay updated on PROMO: Pembrolizumab in Osteosarcoma Clinical Trial
Sign up to get notified when there's something new on the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page.

Latest updates to the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page
- Check3 days agoChange DetectedA site-wide funding/status notice was added and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check10 days agoChange DetectedMinor UI and metadata updates include a glossary toggle, label capitalization tweaks (Last Update Submitted that Met QC Criteria and No FEAR Act data), and a new revision indicator (v3.4.0), which do not alter study data or core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedFooter revision label updated from v3.3.3 to v3.3.4. There are no changes to the study content or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedA new site revision label 'Revision: v3.3.3' appears and the 'HHS Vulnerability Disclosure' link is removed; these are minor UI/site maintenance changes rather than study content updates.SummaryDifference0.1%

- Check75 days agoChange DetectedPublication sourcing text updated to clarify that entries in Publications are auto-filled from PubMed and may not all pertain to the study. The revision tag on the page updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check82 days agoChange DetectedRemoved the site-wide government funding/status notice from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to PROMO: Pembrolizumab in Osteosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROMO: Pembrolizumab in Osteosarcoma Clinical Trial page.